KR101852442B1 - Composition containing ginseng berry extract for preventing or improving bone disease - Google Patents

Abstract

In this specification, a novel use of a composition containing an extract of ginseng fruit as an active ingredient is disclosed. Specifically, the composition containing the ginseng fruit extract of the present invention as an active ingredient increases the bone mineral density and the bone content by improving the degradation of the bone metabolism, and can prevent or improve the bone diseases such as osteoporosis, osteoporosis, And is useful.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing or ameliorating a bone disease containing ginseng fruit extract,

In this specification, a novel use of a composition containing an extract of ginseng fruit as an active ingredient is disclosed.

Normal bone remodeling is a balance of bone formation and bone uptake. These bone formation and bone uptake are largely due to the interaction of three cells, cartilage cells, osteoblasts and osteoclasts. In particular, the proliferation and differentiation of osteoblasts are closely related to bone calcification, and bone metastases do not occur when mutations or decreased expression levels of RUNX2, an important transcription factor in osteoblast cells, occur. It is known that RANKL (receptor activator of NF-kB ligand) is expressed during osteoblast differentiation and regulates osteoclast differentiation. OPG (osteoprotegrin) is also expressed in osteoblasts to inhibit osteoclast differentiation by inhibiting the role of RANKL Is known as an argument. In addition, RANKL is a key inducer of osteoclast differentiation and is known to bind osteoclast-like receptor RANK to promote osteoclast differentiation by regulating the expression of various molecules (for example, T cell) involved in osteoclast differentiation have.

On the other hand, it is known that osteoclast differentiation, formation and activity increase cause hypercalcemia or bone metastasis and increase bone loss in rheumatoid arthritis in some cancers such as osteoporosis induced, solid cancer and hematopoietic malignancy.

Osteoporosis is a disease in which the bone mass is decreased by various causes and the risk of fracture is continuously increased due to the degeneration of the microstructure of the bone tissue. The bone mineral structure (especially calcium) and the matrix are decreased, The formation of balance is broken and osteoclastic activity occurs in the state of increased osteotomy. Inside the normal bone is a dense structure like a net, but in the case of osteoporosis, the widening of the gap between the bone microstructure and the thinning of the microstructure leads to the weakening of the bone, It is categorized as osteoporosis in the elderly, which gradually develops in men and women aged 70 years or older, with progressive bone loss in the pelvic bone and vertebrae, and secondary osteoporosis due to disease, drug, alcohol, smoking and accident regardless of age.

Osteoporosis is one of the most important social problems nowadays. In the United States, about 262,000 women are born every year, of which about 12 to 20% die. As society becomes aging and women become more active in society, fractures caused by osteoporosis and osteoporosis of elderly or postmenopausal women cause serious problems.

Calcium supplementation is the most common method for the prevention of osteoporosis, but calcium supplementation is limited because the bone metabolism itself changes in the elderly.

Takayanagi H., Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems., Nat Rewimmunol. 2007 Apr; 7 (4): p292-304

In one aspect, an object of the present invention is to provide a use of a composition containing an extract of ginseng fruit as an active ingredient for preventing or improving bone diseases.

In another aspect, an object of the present invention is to improve the degradation of bone metabolism.

In another aspect, the object of the present invention is to prevent or ameliorate bone disease through increased bone density or bone content.

In one aspect, the present invention provides a composition for preventing or ameliorating bone diseases, which contains ginseng fruit extract as an active ingredient.

In one aspect, the composition containing the ginseng fruit extract of the present invention as an active ingredient increases the bone mineral density and the bone content by improving the degradation of the bone metabolism, and prevents the bone diseases such as osteoporosis, osteoporosis, osteomalacia and osteoporosis Or improvement.

FIG. 1 shows the results of analysis of ginsenoside components by high performance liquid chromatography (HPLC) of ginseng fruit extract and ginseng root extract.
FIG. 2 shows the effect of ginseng fruit extract on bone mineral density (the vertical axis represents bone mineral density (BMD), and the unit is g / cm ² ).
Fig. 3 shows the effect of ginseng fruit extract on bone content (the vertical axis represents bone mineral content (BMC), and the unit is g).

Hereinafter, the present invention will be described in detail.

In one aspect, the present invention is a composition for preventing or ameliorating osteoporosis, comprising a ginseng fruit extract as an active ingredient.

In the present specification, " Panax ginseng CAMeyer" may mean perennial plants of Araliaceae and may include leaves, roots, tissue cultures, fruits, and seeds. The height is 50 to 60 cm. The stem is straight out from the short, thick rootstock, and the bottom root is separated from the root by one root, which is divided into several branches. Leaves are five leaf-like leaves arranged in a palm-like shape, and they run on the stems from the rootstock. One-year-old leaves grow one by one, and each leaves five to six years after five to six years of harvest. Three years after the buds have emerged, a pale green flower blooms in April-May, with a mountain-shaped inflorescence on the top of the stem. Calyx leaf, petal and stamen are 5 each, and stigma is divided into 2 branches.

As used herein, the term "extract" includes all substances obtained by extracting the components of a natural product, regardless of the extraction method, extraction solvent, extracted component or extract form, The present invention is a broad concept including all substances that can be obtained by processing or treating in other ways. Specifically, the processing or treatment may be an additional fermentation or enzymatic treatment of the extract. Thus, the extract herein is a broad concept including fermentation products, concentrates, and dried products.

In one aspect of the present specification, "ginseng fruit extract" may be ginseng fruit saponin extract. Specifically, in one aspect of the present invention, the ginseng fruit crude saponin extract may be obtained by preparing a ginseng fruit extract, removing the fat-soluble component from the extract, and then extracting it with an organic solvent. More specifically, the ginseng fruit extract may be obtained by adding water or alcohol (for example, 3 L) to the dried ginseng fruit, filtering the mixture at room temperature or refluxing, and concentrating the mixture at 40 to 45 ° C under reduced pressure. The concentration of the alcohol may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%. The organic solvent may be an organic solvent having low polarity, for example, hexane, methylene chloride, ethyl acetate, butanol. Accordingly, in one aspect of the present invention, the crude saponin extract of ginseng fruit may be a soluble fraction of the organic solvent extracted with the organic solvent having a low polarity.

As used herein, "bone disease" may mean a disease that occurs in human bones. Specifically, the bone disease may include, but is not limited to, fracture, metabolic bone disease, congenital bone disease, and degenerative bone disease. In one aspect of the present invention, the bone disease may be at least one selected from the group consisting of osteoporosis, osteoporosis, osteomalacia and osteoarthritis, including but not limited to bone conduction, arthritis , Rheumatoid arthritis, osteoarthritis, degenerative arthritis, discs, osteomalacia, rickets and fibrous dysplasia, hypercalcemia, hyperparathyroidism, hyperparathyroidism, bone metastasis of breast cancer, malignant tumor and malnutrition, traumatic or fatigue fractures .

More specifically, it may include the following bone diseases: osteoporosis, including genetic and congenital forms of osteoporosis, such as primary osteoporosis, endocrine osteoporosis (hyperthyroidism, hyperparathyroidism, Cushing's syndrome and terminal hypertension) Osteogenesis, homocystinuria, menkes syndrome, and Lilly-Day syndrome) and osteoporosis by monofixation. Paget's disease of adult and adolescents (deformed bone); Infectious lesions of bone leading to osteomyelitis or bone loss; Hypercalcemia associated with calcium and hemoglobinemia, endogenous hypercalcemia and hyperparathyroidism and renal dysfunction in tumors (breast, lung and kidney) and hematologic malignancies (multiple myeloma, lymphoma and leukemia); Postoperative osteopenia associated with small bowel disease, chronic liver, renal disease, and induced by steroid administration; Osteonecrosis or osteoclast associated with trauma, or non-traumatic necrosis associated with osteoporosis, sickle anemia, systemic lupus erythematosus and other conditions; Bone loss due to rheumatoid arthritis; Dental caries bone loss; And osteolytic metastasis.

In one aspect of the present invention, the composition may contain crude saponin in an amount of 25 wt% or more based on the total dry weight of the ginseng fruit extract.

The crude saponin content is at least 24% by weight, at least 25% by weight, at least 27% by weight, at least 29% by weight, at least 31% by weight and at least 32% by weight, based on the total dry weight of the ginseng fruit extract , 33 wt% or more, 34 wt% or more, 35 wt% or more, 36 wt% or more, 37 wt% or more, 38 wt% or more, but is not limited thereto.

In one aspect of the present invention, the ginseng fruit extract comprises 1.0-2.0 wt% of ginsenoside Rb1 (wt%), 2.0-2.4 wt% of Rb2 At least one selected from the group consisting of 0.5 to 1.2% by weight of Rb3, 3.5 to 4.5% by weight of Rc, 4.0 to 6.0% by weight of Rd, 15.0 to 19.0% by weight of Re, 0.6 to 2.0% by weight of Rg1 and 0.5 to 1.2% But is not limited thereto.

More specifically, the ginsenoside Rb1 is present in an amount of 0.9 wt% or more, 1.0 wt% or more, 1.1 wt% or more, 1.3 wt% or more, 1.5 wt% or more, 1.7 wt% or more, 1.8 wt% or more, 1.9 wt% 2.1 wt% or less, 2.1 wt% or less, 2.1 wt% or less, 2.1 wt% or less, 2.1 wt% or less, 2.1 wt% or less, 2.0 wt% or less, 1.9 wt% or less, 1.7 wt% or less, Or less, 1.5 wt% or less, 1.3 wt% or less, 1.1 wt% or less, 1.0 wt% or less. The ginsenoside Rb2 may be present in an amount of 1.9 wt% or more, 2.0 wt% or more, 2.1 wt% or more, 2.5 wt% or more, 2.9 wt% or more, 3.3 wt% or more, 3.7 wt% or more, 3.9 wt% Or less, and may be 4.1 wt% or less, 3.8 wt% or less, 3.4 wt% or less, 3.0 wt% or less, 2.6 wt% or less, 2.2 wt% or less, 2.0 wt% or less. The ginsenoside Rb3 may be at least 0.4 wt%, at least 0.5 wt%, at least 0.7 wt%, at least 0.9 wt%, at least 1.1 wt%, at least 1.2 wt%, at most 1.3 wt%, at most 1.2 wt% , 0.9 wt% or less, 0.7 wt% or less, 0.5 wt% or less, 0.4 wt% or less. The ginsenoside Rc may be at least 3.4 wt%, at least 3.5 wt%, at least 3.8 wt%, at least 4.1 wt%, at least 4.4 wt%, at least 4.5 wt%, at least 4.6 wt% , 4.5 wt% or less, 4.2 wt% or less, 3.9 wt% or less, 3.6 wt% or less, 3.5 wt% or less. The ginsenoside Rd may also contain at least 3.9 wt%, at least 4.0 wt%, at least 4.3 wt%, at least 4.6 wt%, at least 4.9 wt%, at least 5.2 wt%, at least 5.5 wt%, at least 5.8 wt% , Not more than 6.1 wt%, not more than 6.0 wt%, not more than 5.7 wt%, not more than 5.4 wt%, not more than 5.1 wt%, not more than 4.8 wt%, not more than 4.5 wt%, not more than 4.2 wt% , 4.0 wt% or less. Also, the ginsenoside Re is at least 14.9 wt%, at least 15.0 wt%, at least 15.7 wt%, at least 16.4 wt%, at least 17.1 wt%, at least 17.8 wt%, at least 18.5 wt%, at least 18.9 wt% Or less, and may be 19.1 wt% or less, 19.0 wt% or less, 18.3 wt% or less, 17.6 wt% or less, 16.9 wt% or less, 16.2 wt% or less, 15.5 wt% or less and 15.0 wt% or less. The ginsenoside Rg1 may be at least 0.5 wt%, at least 0.6 wt%, at least 0.9 wt%, at least 1.2 wt%, at least 1.5 wt%, at least 1.8 wt%, at least 2.0 wt%, at least 2.1 wt% , 2.1 wt% or less, 2.0 wt% or less, 1.7 wt% or less, 1.4 wt% or less, 1.1 wt% or less, 0.8 wt% or less, 0.6 wt% or less. The ginsenoside Rg2 may be at least 0.4 wt%, at least 0.5 wt%, at least 0.7 wt%, at least 1.0 wt%, at least 1.2 wt%, at least 1.3 wt%, at most 1.3 wt%, at most 1.2 wt% , 0.9 wt% or less, 0.6 wt% or less, 0.5 wt% or less, but is not limited thereto.

In a composition for prevention or improvement of bone disease according to one aspect of the present invention, the ginseng fruit extract is a composition for preventing or ameliorating osteoporosis of protopanaxadiol (PD) ginsenoside (Protopanaxadiol, PT) against ginsenoside of protopanaxatriol The dry weight ratio PD / PT may be 0.3 to 1.2, and may be 0.2 or more, 0.3 or more, 0.5 or more, 0.7 or more, 0.9 or more, 1.1 or more, 1.2 or more, 1.3 or more, , Not more than 1.0, not more than 0.8, not more than 0.6, not more than 0.4, not more than 0.3 and not more than 0.2, but is not limited thereto.

In view of the above, the protopanaxadiol-based ginsenoside may comprise at least one member selected from the group consisting of ginsenosides Re, Rg1 and Rg2, and the protopanaxidiol-based ginsenoside (PD) , Ginsenosides Rb1, Rb2, Rc and Rd.

The composition for prevention or improvement of bone diseases according to one aspect of the present invention may contain 0.001 to 0.2 wt% 0,015 wt% or more, 0,055 wt% or more, 0,075 wt% or more, 0,1 wt% or more, 0,13 wt% or more, 0,15 wt% or more, 0,17 wt% or more, 0,19 wt% 0.001 wt.% Or less, 0.004 wt.% Or less, 0.004 wt.% Or less, 0.002 wt.% Or less, and 0.1 wt.% Or less, By weight or less, but is not limited thereto.

In addition, in the composition for preventing or alleviating bone diseases which is one aspect of the present invention, the ginseng fruit extract may be any one or more extracts selected from the group consisting of flesh of flesh of ginseng, perilla, and combination of flesh and perilla.

In the composition for prevention or improvement of bone disease according to one aspect of the present invention, the ginseng fruit extract may be at least one extract selected from the group consisting of water, organic solvent and mixture thereof.

In view of the above, the organic solvent may be at least one selected from the group consisting of C1-C6 lower alcohols, butylene glycol, and propylene glycol. Specifically, the C1-C6 lower alcohol may be at least one selected from the group consisting of methanol, , Ethyl acetate, diethyl ether, ethyl methyl ketone, and chloroform, but may include all organic solvents known to those skilled in the art.

Further, in view of the above, the lower alcohol may be ethanol but is not limited thereto.

In a composition for preventing or improving a bone disease, which is one aspect of the present invention, the bone disease may be caused by a decrease in bone density or a bone content.

As used herein, the term " bone mineral density "refers to a measure of the mineral content of bone, which may mean the density of minerals present in the bone and which is problematic in relation to bone development, particularly osteoporosis .

In the present specification, "bone mineral content" may mean the content of minerals present in the bone.

&Quot; Reduction "in this specification may mean a decrease in amount or value, may mean loss, and may mean falling below the normal bone density and bone content values of the object, This may mean that the value of the content falls below the value of the normal person.

In addition, in the composition for preventing or improving bone diseases, which is an aspect of the present invention, the composition may be a pharmaceutical composition or a health food, but is not limited thereto.

Specifically, the composition may be formulated as a pharmaceutical composition or a food composition in the form of tablets, pills, tablets, capsules, granules, powders, ointments, drinks or injections.

The composition of the present invention can be prepared into a pharmaceutical formulation according to a conventional method. In the preparation of the formulations, it is preferred that the active ingredient is mixed with or diluted with the carrier, or enclosed in a carrier in the form of a container. When the carrier is used as a diluent, it may be a solid, semi-solid or liquid substance acting as a carrier, excipient or medium for the active ingredient. Thus, the formulations may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injections, sterile powders and the like.

Examples of suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, Hydroxybenzoate, talc, magnesium stearate, and mineral oil. The formulations may additionally include fillers, anti-coagulants, lubricants, wetting agents, perfumes, emulsifiers, preservatives, and the like. The compositions of the present invention may be formulated using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal.

The pharmaceutical composition of the present invention may be administered through various routes including oral, transdermal, subcutaneous, intravenous, intraperitoneal, muscle, topical application, patch and iontophoresis, and local application and oral administration are preferred Do.

In the case of humans, the usual daily dose of the active compound may range from 1 to 100 mg / kg body weight, preferably from 5 to 70 mg / kg body weight, and may be administered in single or divided doses. It should be understood, however, that the actual dosage of the active ingredient should be determined in light of various relevant factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease, Are not intended to limit the scope of the invention.

In addition, the health food is produced by using a raw material or a component (functional raw material) having a useful function for a nutrient or a human body which is likely to be deficient in a daily meal and maintains the health through maintaining the normal function of the human body or activating the physiological function But is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles, but is not limited thereto and may be manufactured and processed in any form according to the law.

In one aspect of the present invention, the health beverage composition is not particularly limited to other ingredients other than the above-mentioned compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages have. Examples of natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings other than those described above.

In general, the effective amount administered by a health food composition may range from 0.001 mg / kg / day to about 2000 mg / kg / day. A more preferred dosage may be 0.5 mg / kg / day to 2.5 mg / kg / day. The administration may be carried out once a day or divided into several times.

Hereinafter, the present invention will be described more specifically with reference to the following examples. However, the following examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.

[Example 1] Preparation of fruit extract of Panax ginseng C. A. Meyer

[Example 1-1] Pretreatment of ginseng fruit

The raw ginseng fruit was harvested and the seeds were separated and removed. Then, the ginseng fruit and the peel of the ginseng fruit were dried in sunlight or hot air to prepare dry ingredients of ginseng fruit.

[Example 1-2] Preparation of ginseng fruit extract

3 kg of 70% alcohol was added to 1 kg of dried ginseng fruit, and the mixture was refluxed, filtered and concentrated under reduced pressure at 40 to 45 ° C to obtain 300 g of ginseng fruit extract.

[Experimental Example 1] Preparation of ginseng muscle root extract

In Example 1, ginseng root extract was prepared in the same manner as in Example 1, except that ginseng root (root) was used instead of ginseng fruit.

[Example 2] Comparison of components of ginseng fruit extract

[Example 2-1] Analysis of ginsenoside components of ginseng fruit and ginseng root

Ginseng root extract and ginseng root extract were prepared in Example 1 and Experimental Example 1, respectively. Then, the extract was treated with ether to remove fat-soluble components, then crude saponin was extracted with butanol (BuOH) The results are shown in FIG. 1 and Table 1 below.

Ginseng fruit extract Ginseng root extract Crude saponin content (dry weight) 33.42% 16.70% PD / PT 0.73 3.23

As can be seen from FIG. 1 and Table 1, the ginseng fruit extract had about twice the content of crude ginseng root extract prepared in Experimental Example 1 in terms of crude saponin content, and ginsenoside was treated with protopanaxadiol , PD) When we divided the ratio of "ginsenosides Rb1, Rb2, Rc and Rd" and protopanaxatriol (PT) "ginsenoside Re, Rg1 and Rg2" Therefore, it was confirmed that the ginseng root and ginseng root were distinctly different from each other.

[Example 2-2] Mineral composition analysis of ginseng fruit extract

Mineral components including vitamins were analyzed to determine the difference between the ginseng fruit extract prepared in Example 1 and ginseng. The results are shown in Table 2 below.

ingredient content potassium 5865.57 mg / 100g calcium 819.26 mg / 100 g iron 59.31 mg / 100 g sign 187.17 mg / 100 g Vitamin A 213.11 ug / 100 g, RE Vitamin B1 12.29 mg / 100 g Vitamin B2 8.45 mg / 100 g Vitamin B6 10.50 mg / 100 g Vitamin C 4.91 mg / 100 g Vitamin E 23.61 mg / 100 g a-TE Vitamin K 232.12 mg / 100g Pantothenic acid 5.87 mg / 100 g magnesium 354.38 mg / 100 g zinc 178.49 mg / 100 g Niacin 5.76 mg / 100 g, NE Folic acid 349.97 / / 100g

[Example 3] Measurement of improvement in degradation of bone metabolism by aging

[Example 3-1] Preparation of control group and experimental group

Male 15-month-old C57 / BL6 rats were divided into 15 rats per group, and the bone metabolism-related indicators were analyzed for 32 weeks after feeding the diets shown in Table 3 below.

The control group was a group consisting of 15-month-old C57 / BL6 rats fed only with the AIN-93G diet shown in the following Table 3. Experimental group 1 was a group consisting of rats fed with only the AIN-93G diet shown in Table 3 below for 32 weeks in the control rats , And experimental group 2 is a group consisting of rats fed with the 0.05% of ginseng fruit extract to the mice of the control group for 32 weeks in the AIN-93G diet shown in Table 3 below. All feeds to the control and experimental groups were gamma irradiated.

Composition of AIN-93G ingredient Content (g / kg) Casein 200.00 Cornstarch 397.486 Dyetrose 132.00 Sucrose 100.00 Cellulose 50.00 Soybean oil 70.00 t-butylhydroquinone (t-butylhydroquinone) 0.014 Salt mix 35.00 Vitamin mix 10.00 L-cystine 3.00 Choline bitartrate 2.50

[Example 3-2] Measurement and analysis of bone mineral density

Bone density was analyzed using pDEXA Saber software (version 3.9.4; Norland) using peripheral dual-energy X-ray absorptiometry (pDEXA) (SabreTM; Norland Medical Systems Corp., Fort Atkinson, WI, USA) Bone density analysis was performed by dividing the femoral head of the mouse and measuring the bone density at a rate of 20 mm per second at a resolution of 0.2 × 0.2 mm.

As a result, as shown in FIG. 2, in the group receiving the 0.05% diet of ginseng fruit extract for 32 weeks (experimental group 2), the bone density of the femur compared with the group receiving the ginseng fruit- (32 weeks) was higher than that of 15-month-old rats (control group).

[Example 3-3] Measurement and analysis of bone mineral content

The bone content was measured in the same manner as in [Example 3-2].

As a result, as shown in FIG. 3, in the group that received the 0.05% diet of ginseng fruit extract for 32 weeks (experimental group 2), compared with the group that received no ginseng fruit extract (experimental group 1) (32 weeks old) was higher than that of 15 month old rats (control group).

Hereinafter, a formulation example of the composition according to the present invention will be described. However, the pharmaceutical composition and the cosmetic composition can be applied to various formulations, which are not intended to limit the present invention but merely to illustrate the present invention.

[Formulation Example 1] Production of pills

30% by weight of ginseng (Panax ginseng C. A. Meyer) fruit extract, 30% by weight of corn starch, 20% by weight of glycerin and 20% by weight of sorbitol powder prepared in Example 1 were mixed and a ring was prepared using a ventilator. The final weight of the contents was 3.5 g.

[Formulation Example 2] Preparation of tablet

30% by weight of ginseng (Panax ginseng CA Meyer) extract prepared in Example 1, 20.5% by weight of lactose, 20% by weight of dextrin, 20% by weight of maltitol powder and 7% by weight of xylitol powder were mixed, After granulating, 2.5% by weight of sugar ester was added and the tablet was tableted. The final weight of the contents was 2 g.

[Formulation Example 3] Preparation of granules

30% by weight of ginseng (Panax ginseng C. A. Meyer) extract prepared in Example 1, 5% by weight of xylitol and 65% by weight of isomalt were mixed and granulated into granules using a fluidized bed granulator. The final weight of the contents was 2 g.

[Formulation Example 4] Preparation of injection

Injectables were prepared in a conventional manner according to the composition shown in Table 4 below.

Compounding ingredient content The ginseng fruit extract of Example 1 10-50 mg Sterile sterilized water for injection Suitable amount pH adjusting agent Suitable amount

[Formulation Example 5] Health food

Healthy foods were prepared in a conventional manner according to the compositions shown in Table 5 below.

Compounding ingredient content The ginseng fruit extract of Example 1 20 mg Vitamin A acetate 70 μg Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 μg Vitamin C 10 mg Biotin 10 μg Nicotinic acid amide 1.7 mg Folic acid 50 μg Calcium pantothenate 0.5 mg Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

[Formulation Example 6] Health drinks

Health drinks were prepared according to the compositions shown in Table 6 below in a conventional manner.

Compounding ingredient content The ginseng fruit extract of Example 1 1000 mg Citric acid 1000 mg oligosaccharide 100 g Taurine 1g Purified water Balance

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (14)

The present invention relates to a composition for preventing or ameliorating a bone disease, comprising a ginseng fruit extract as an active ingredient,
The ginseng fruit extract comprises ginsenosides, vitamins and minerals,
Wherein the bone disease is at least one selected from the group consisting of osteoporosis, osteoporosis, osteomalacia and osteoarthritis. The method according to claim 1,
The composition may comprise,
Wherein the crude saponin content is at least 25 wt% (wt%) based on the total dry weight of the ginseng fruit extract. The method according to claim 1,
The ginseng fruit extract,
1.0 to 2.0% by weight of ginsenoside Rb1, 2.0 to 4.0% by weight of Rb2, 0.5 to 1.2% by weight of Rb3, 3.5 to 4.5% by weight of Rc and 4.0 to 6.0% by weight of Rd based on the total dry weight of crude saponin, By weight of Re, 15.0 to 19.0% by weight of Re, 0.6 to 2.0% by weight of Rg1, and 0.5 to 1.2% by weight of Rg2. The method according to claim 1,
The ginseng fruit extract,
Wherein the dry weight ratio (PD / PT) of the protopanaxadiol (PD) ginsenoside to Protopanaxatriol. Tin oleate is 0.3 to 1.2. 5. The method of claim 4,
Wherein the protoplanary triol (PT) ginsenoside comprises at least one member selected from the group consisting of ginsenosides Re, Rg1 and Rg2,
The protopanaxidiol-based (PD) ginsenosides are selected from the group consisting of ginsenosides Rb1, Rb2, Rc and
Rd. ≪ / RTI > The method according to claim 1,
Wherein the ginseng fruit extract is contained in an amount of 0.001 to 0.2% by weight. The method according to claim 1,
The ginseng fruit extract,
Wherein the composition is any one or more extracts selected from the group consisting of pulp, perilla, flesh and perilla of ginseng fruit. The method according to claim 1,
The ginseng fruit extract,
Wherein the composition is at least one extract selected from the group consisting of water, organic solvents, and mixtures thereof. 9. The method of claim 8,
The organic solvent may include,
C1 to C6 lower alcohols, butylene glycol, and propylene glycol. 10. The method of claim 9,
Wherein the lower alcohol is ethanol. delete delete 11. The method according to any one of claims 1 to 10,
Wherein the composition is a pharmaceutical composition. 11. The method according to any one of claims 1 to 10,
Wherein the composition is a health food.

Images